No abstract

No abstract

Background:No consensus exists regarding the anatomic characteristics of the knee anterolateral ligament (ALL). A critical analysis of the dissections described in previous studies allows the division of the ALL into 2 groups with similar characteristics. The presence of considerable variability suggests that the authors may not be referring to the same structure.Purpose/Hypothesis:To perform a lateral anatomic dissection, by layers, seeking to characterize the 2 variants described for the ALL on the same knee. We hypothesized that we would identify the 2 variants described for the ALL and that these variants would have distinct characteristics.Study Design:Descriptive laboratory study.Methods:Thirteen unpaired cadaveric knees were used in this study. The dissection protocol followed the parameters described in previous studies. Immediately below the iliotibial tract, we isolated a structure designated as the superficial ALL, whereas between this structure and the articular capsule, we isolated a structure designated as the deep ALL. The 2 structures were measured for length at full extension and at 90° of flexion and for distance from the tibial insertion relative to the Gerdy tubercle. Potential contact with the lateral meniscus was also evaluated. After measurements were obtained, the 2 dissected structures underwent histologic analysis.Results:The superficial ALL presented a posterior and proximal origin to the center of the lateral epicondyle, its length increased on knee extension, and it exhibited no contact with the lateral meniscus. The deep ALL was located in the center of the lateral epicondyle, its length increased on knee flexion, and it presented a meniscal insertion. Both structures had a similar tibial insertion site; however, the insertion site of the deep ALL was located more posteriorly. The analysis of the histological sections for both structures indicated the presence of dense and well-organized collagen fibers.Conclusion:This anatomic study clearly identified 2 structures, described as the superficial and deep ALL, which were consistent with previous but conflicting descriptions of the ALL.Clinical Relevance:This study clarifies numerous controversies encountered in anatomic studies of the ALL. Knowledge regarding the existence of 2 distinct structures in the anterolateral knee will allow more accurate evaluation of their functions and characteristics.

The findings of this study help to better understand the ALL's anatomy and histology from the fetal period to adulthood. The study presents the existence of the ALL since fetal development, emphasizes the characterization of the ALL, and brings important information to future pediatric ALL lesion studies.

We have investigated Amblyomin-X-treated horse melanomas to better understand its mode of action through transcriptome analysis and the in vivo model. Amblyomin-X is a Kunitz-type homologous protein that selectively leads to the death of tumor cells via ER stress and apoptosis, currently under investigation as a new drug candidate for cancer treatment. Melanomas are immunogenic tumors, and a better understanding of the immune responses is warranted. Equine melanomas are spontaneous and not so aggressive as human melanomas are, as this study shows that the in vivo treatment of encapsulated horse melanoma tumors led to a significant reduction in the tumor size or even the complete disappearance of the tumor mass through intratumoral injections of Amblyomin-X. Transcriptome analysis identified ER-and mitochondria-stress, modulation of the innate immune system, apoptosis, and possibly immunogenic cell death activation. Interactome analysis showed that Amblyomin-X potentially interacts with key elements found in transcriptomics. Taken together, Amblyomin-X modulated the tumor immune microenvironment in different ways, at least contributing to induce tumor cell death. Melanoma is a type of cancer arising from the malignant transformation of melanocytes, pigment producing-cells found predominantly in the basal layer of the epidermis and eyes. Cutaneous melanoma is the most aggressive and treatment-resistant form of skin cancer responsible for the vast majority of skin cancer-related deaths in the Caucasian population 1. The global incidence of melanoma continues to increase at an alarming rate, despite decades of public prevention programs in many countries. Around 232,000 new cases of skin cancer were recorded worldwide in 2012, accounting for 1.6% of all new cases of cancer back then, while over 300,000 new cases of melanoma were diagnosed worldwide in 2018, according to the World Cancer Research Foundation 2,3. In Brazil, 1,547 deaths were recorded in 2013 due to melanoma, with around 5,690 new cases reported back then, while around 6,260 new cases were expected due in 2018, according to the National Cancer Institute (INCA) 4. Cutaneous melanoma usually affects a higher proportion of patients, in the age range 40-60 years. They can be treated by surgical excision when detected in the early stage (0, I, II and resectable III), however, in the later stages (unresectable III, IV and recurrent melanoma) the treatment options are chemotherapy, target therapy (BRAF/ MEK pathway inhibitors), immunotherapy (checkpoint blockade CTLA-4 receptor inhibition, PD-1 ↔ PD-L1 axis inhibition, and interferon-gamma immunotherapy), or a combination of them. Death in most patients is caused by metastatic disease which may have evolved from the primary tumor. Therefore, there is a need for new